After oral administration, it reaches peak plasma concentrations within one and a half hours. Patients taking enzyme-inducing anticonvulsants have lower plasma concentrations, while patients taking sodium valproate were markedly higher.<ref>{{cite journal | pmc = 1368527 | year = 1991 | author1 = Tartara | first1 = A | title = Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients | journal = British Journal of Clinical Pharmacology | volume = 32 | issue = 3 | pages = 335–340 | last2 = Galimberti | first2 = C. A. | last3 = Manni | first3 = R | last4 = Parietti | first4 = L | last5 = Zucca | first5 = C | last6 = Baasch | first6 = H | last7 = Caresia | first7 = L | last8 = Mück | first8 = W | last9 = Barzaghi | first9 = N | last10 = Gatti | first10 = G | last11 = Perucca | first11 = E | pmid = 1777370 | doi=10.1111/j.1365-2125.1991.tb03908.x}}</ref>

 
==Side-effects==

 
The FDA has classified the side effects into groups based on dosages levels at q4h. For the high dosage group (90&nbsp;mg) less than 1% of the group experienced adverse conditions including itching, gastrointestinal hemorrhage, thrombocytopenia, neurological deterioration, vomiting, [[diaphoresis]], [[congestive heart failure]], hyponatremia, decreasing platelet count, disseminated intravascular coagulation, deep vein [[thrombosis]].<ref name=Lbl/>
